Sugi Predict

Sugi Predict / Compounds / SCHEMBL2125576

SCHEMBL2125576

SCHEMBL2125576

CC(C)(C)OC(=O)N1C2CCC1(CO)CC2

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ CHRM2 P08172 1/20 0.41
▸ CHRM1 P11229 1/20 0.41
▸ CHRM3 P20309 1/20 0.41
▸ NR1H2 P55055 1/20 0.39
▸ HPGD P15428 1/20 0.38
▸ PREP P48147 3/20 0.38
▸ CTSK P43235 1/20 0.36
▸ EPHX1 P07099 1/20 0.36
▸ DDB1 Q16531 1/20 0.36
▸ CRBN Q96SW2 1/20 0.36
▸ MEN1 O00255 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ ABCB1 P08183 1/20 0.35
▸ KDM1A O60341 1/20 0.33
▸ SPHK1 Q9NYA1 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29851796 0.95 CHRM2 (0.39) CHRM2CHRM1CHRM3NR1H2HPGD
Lithium Ion SCHEMBL29474793 0.90 CHRM2 (0.35) CHRM2CHRM1CHRM3NR1H2HPGD
SCHEMBL26759053 0.87 CHRM2 (0.41) CHRM2CHRM1CHRM3NR1H2HPGD
SCHEMBL25328629 0.86 CHRM2 (0.41) CHRM2CHRM1CHRM3NR1H2HPGD
SCHEMBL16391852 0.86 CHRM2 (0.41) CHRM2CHRM1CHRM3NR1H2HPGD
SCHEMBL30998687 0.86 CHRM2 (0.39) CHRM2CHRM1CHRM3NR1H2HPGD
SCHEMBL16249849 0.84 SPHK1 (0.36) CHRM2CHRM1CHRM3NR1H2HPGD
SCHEMBL30968002 0.83 CHRM2 (0.39) CHRM2CHRM1CHRM3NR1H2HPGD
SCHEMBL11964216 0.83 CHRM2 (0.39) CHRM2CHRM1CHRM3NR1H2HPGD
SCHEMBL22370300 0.82 CHRM2 (0.41) CHRM2CHRM1CHRM3NR1H2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3710458-B1 IMMUNOPROTEASOME INHIBITORS PRINCIPIA BIOPHARMA INC (US) 2026-03-25 — — EP disclosed
EP-4580620-A2 PYRAZOLE AND IMIDAZOLE DERIVATIVES AS DUAL OREXIN AND KAPPA-OPIOID RECEPTORS MODULATORS, COMPOSITION, METHODS FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS Hager Biosciences, LLC (US) 2025-07-09 — — EP disclosed
US-12312370-B2 Immunoproteasome inhibitors PRINCIPIA BIOPHARMA INC. (US) 2025-05-27 — — US disclosed
US-20240254136-A1 COMPOUNDS TARGETING RNA-BINDING PROTEINS OR RNA-MODIFYING PROTEINS Redona Therapeutics, Inc. 2024-08-01 — — US disclosed
US-20240238285-A1 POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE GILEAD SCIENCES, INC. 2024-07-18 — — US disclosed
US-20240238285-A1 POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE GILEAD SCIENCES, INC. 2024-07-18 — — US disclosed
US-20240199655-A1 Immunoproteasome Inhibitors PRINCIPIA BIOPHARMA INC. (US) 2024-06-20 — — US disclosed
CN-111491938-B Immunoproteasome inhibitors 普林斯匹亚生物制药公司 2024-05-24 — — CN disclosed
WO-2024050061-A2 PYRAZOLE AND IMIDAZOLE DERIVATIVES AS DUAL OREXIN AND KAPPA-OPIOID RECEPTORS MODULATORS, COMPOSITION, METHODS FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS HAGER BIOSCIENCES, LLC (US) 2024-03-07 — — WO disclosed
US-11827656-B2 Immunoproteasome inhibitors PRINCIPIA BIOPHARMA INC. (US) 2023-11-28 — — US disclosed
US-9458159-B2 Substituted pyrido[1′,2′:4,5]pyrazino[1,2-a]azepines for treating viral infections GILEAD SCIENCES, INC. (US) 2016-10-04 — — US disclosed
WO-2015006733-A1 POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF HIV INFECTIONS GILEAD SCIENCES, INC. (US) 2015-01-15 — — WO disclosed
US-20120094995-A1 2-AZA-BICYCLO[2.2.1]HEPTANE COMPOUNDS AND USES THEREOF ASTRAZENECA AB (SE) 2012-04-19 — — US disclosed
US-20120094995-A1 2-AZA-BICYCLO[2.2.1]HEPTANE COMPOUNDS AND USES THEREOF ASTRAZENECA AB (SE) 2012-04-19 — — US disclosed
US-20120094995-A1 2-AZA-BICYCLO[2.2.1]HEPTANE COMPOUNDS AND USES THEREOF ASTRAZENECA AB (SE) 2012-04-19 — — US disclosed
EP-2391628-A1 2-AZA-BICYCLOÝ2.2.1¨HEPTANE COMPOUNDS AND USES THEREOF AstraZeneca AB (SE) 2011-12-07 — — EP disclosed
WO-2010087762-A1 2-AZA-BICYCLO[2.2.1]HEPTANE COMPOUNDS AND USES THEREOF ASTRAZENECA AB (SE) 2010-08-05 — — WO disclosed
WO-2010087762-A1 2-AZA-BICYCLO[2.2.1]HEPTANE COMPOUNDS AND USES THEREOF ASTRAZENECA AB (SE) 2010-08-05 — — WO disclosed
EP-0842178-B1 FUROPYRIDINE, THIENOPYRIDINE, PYRROLOPYRIDINE AND RELATED PYRIMIDINE, PYRIDAZINE AND TRIAZINE COMPOUNDS USEFUL IN CONTROLLING CHEMICAL SYNAPTIC TRANSMISSION ABBOTT LAB (US) 2001-03-28 — — EP disclosed
US-6001849-A Furopyridine, thienopyridine pyrrolopyridine useful in controlling chemical synaptic transmission ABBOTT LABORATORIES (US) 1999-12-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11827656-B2 Immunoproteasome inhibitors PSMC2, PSMB7, PSMB2 CHRM2 4725/4885CHRM1 4823/4885CHRM3 4812/4885
US-20240199655-A1 Immunoproteasome Inhibitors PSMC2, PSMB7, PSMB2 CHRM2 4725/4885CHRM1 4823/4885CHRM3 4812/4885
US-20240238285-A1 POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE CCND3, PRCP, ZC3HAV1 CHRM2 94/4885CHRM1 45/4885CHRM3 221/4885
US-12312370-B2 Immunoproteasome inhibitors PSMC2, PSMB7, PSMB2 CHRM2 4725/4885CHRM1 4823/4885CHRM3 4812/4885
US-20240254136-A1 COMPOUNDS TARGETING RNA-BINDING PROTEINS OR RNA-MODIFYING PROTEINS NSUN3, NSUN2, RBM3 CHRM2 4875/4885CHRM1 4833/4885CHRM3 4775/4885
US-20120094995-A1 2-AZA-BICYCLO[2.2.1]HEPTANE COMPOUNDS AND USES THEREOF SLC1A2, B4GALT1, SLC6A1 CHRM2 2988/4885CHRM1 1791/4885CHRM3 3272/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.